リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61)」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61)

YAGI Noriharu KOMIYA Ichiro ARAI Keiko OISHI Mariko FUKUMOTO Yoshihide SHIRABE Shunichirou YOKOYAMA Hiroki YAMAZAKI Katsuya SUGIMOTO Hidekatsu MAEGAWA Hiroshi 00209363 0000-0002-4611-8149 滋賀医科大学

2022.01

概要

Aims/Introduction:
Type 2 diabetes mellitus is caused by a relative imbalance between insulin secretion and sensitivity related to the body mass index (BMI). Seven categories of oral antidiabetic drugs (OADs) are available in Japan. It is important to assess the OAD utilization patterns based on patients’ BMI levels.
Materials and methods:
OAD prescribing patterns from 2002 to 2019 were analyzed using the data collected in the computerized diabetes care database provided by the Japan Diabetes Clinical Data Management Study Group; OAD utilization patterns in 25,751 OAD-treated type 2 diabetes mellitus patients registered in 2019 were analyzed after classifying them into five categories of BMI.
Results:
Comparing OAD usage between 2002 and 2019, sulfonylureas decreased from 44.5 to 23.2%, and biguanides (BGs) increased from 19.3 to 50.3%. Dipeptidyl peptidase-4 inhibitors (DPP4is) increased to 56.9% in 2019. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) increased to 23.6% in 2019. About 90% of type 2 diabetes mellitus patients had BMI < 30 kg/m2 . DPP4is were the most used OADs in 2019. When BMI exceeded 30 kg/m2 , use of BGs and sodium-glucose cotransporter 2 inhibitors increased, and use of sulfonylureas and DPP4is decreased. Although DPP4is were the most used OADs for patients with BMI <30 kg/m2 , they were the third most prescribed OADs for patients with BMI >35 kg/m2 after BGs and sodium-glucose cotransporter 2 inhibitors .
Conclusions:
DPP4i usage was as high as that of BG in the analysis of Japanese type 2 diabetes mellitus patients with relatively low BMI. This was considered to be a treatment option appropriate for the pathophysiology in Japanese patients.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. IDF Diabetes ATLAS, 9th edn. 2019. Available from: https:// www.diabetesatlas.org/en/. Accessed January 11, 2021.

2. The National Health and Nutrition Survey (NHNS) Japan. 2016; Available from: https://www.nibiohn.go.jp/eiken/ke nkounippon21/download_files/eiyouchousa/2016.pdf. Accessed January 11, 2021.

3. Oishi M, Yamazaki K, Okuguchi F, et al. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32). J Diabetes Investig 2014; 5: 581–587.

4. Ozawa H, Murai Y, Ozawa TA. 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus. Yakushigaku Zasshi 2003; 38: 11–27. (Japanese).

5. Davies MJ, D’Alessio DA, Fradkin J, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 2018: 2669–2701.

6. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 2019; 42: S90–S102.

7. Lipscombe L, Booth G, Butalia S, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes 2018; 2018: 575. Erratum in: Can J Diabetes 2018; 42: 575.

8. Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig 2020; 11: 1020–1076.

9. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 2013; 1281: 64–91.

10. Møller JB, Pedersen M, Tanaka H, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care 2014; 37: 796–804.

11. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66: S37–S43.

12. Kim D-J, Lee M-S, Kim K-W, et al. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism 2001; 50: 590–593.

13. Qian L, Xu L, Wang X, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev 2009; 25: 144–149.

14. Kobayashi M, Yamazaki K, Hirao K, et al. Japan Diabetes Clinical Data Management Study Group. The status of diabetes control and antidiabetic drug therapy in Japan–a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006; 73: 198–204.

15. Japan Diabetes Clinical Data Management Study Group [Japanese] Available from: http://jddm.jp/. Accessed January 17, 2021.

16. Kanda Y. Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–458.

17. Montvida O, Shaw J, Atherton JJ, et al. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care 2018; 41: 69–78.

18. Engler C, Leo M, Pfeifer B, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018. BMJ Open Diabetes Res Care. 2020; 8: e001279. https://doi.org/10.1136/bmjdrc-2020-001279.

19. Chu W-M, Ho H-E, Huang K-H, et al. The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: an 8-year population-based study. Medicine (Baltimore). 2017; 96: e8257. https://doi.org/10.1097/MD.0000000000008257.

20. Ko S-H, Kim D-J, Park J-H, et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013: Nationwide population-based cohort study. Medicine (Baltimore) 2016; 95: e4018. https://doi.org/10.1097/MD.0000000000004018.

21. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865. Erratum. In: Lancet1998; 1998: 1558.

22. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig 2014; 5: 475–477.

23. Cleveland JC, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997; 96: 29–32.

24. Ovu€n c K. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol 2000; 23: 535–539.

25. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.

26. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

27. Yamamoto-Honda R, Takahashi Y, Mori Y, et al. Changes in antidiabetic drugs prescription and glycemic control trends in elderly patients with type 2 diabetes mellitus from 2005–2013: an analysis of the National Center Diabetes Database (NCDD-03). Intern Med 2018; 57: 1229–1240.

28. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992; 15: 318–368.

29. Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care 2011; 34: 1424–1430.

30. Kojta I, Chacin´ska M, Błachnio-Zabielska A. Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. Nutrients 2020; 12: nu12051305.

31. Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose- lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696–708.

32. Kohro T, Yamazaki T, Sato H, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J 2013; 54: 93–97.

33. Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives. J Diabetes Investig 2016; 7: S102–S109.

34. Bays HE, Chapman RH, Grandy S, et al. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007; 61: 737–747. Erratum. In: Int J Clin Pract 2007; 2007: 1777–1778.

35. Iwahashi H, Okauchi Y, Ryo M, et al. Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients. J Diabetes Investig 2012; 3: 271–275.

36. Yabe D, Seino Y, Fukushima M, et al. b cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep 2015; 15: 602.

37. Murayama H, Imai K, Odawara M. Factors influencing the prescribing preferences of physicians for drug-naive patients with type 2 diabetes mellitus in the real-world setting in Japan: Insight from a web survey. Diabetes Ther 2018; 9: 1185–1199.

38. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 2021; 44: S111-S124.

39. Boffetta P, McLerran D, Chen YU, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One 2011; 6: e19930.

40. Lee JW, Brancati FL, Yeh HC. Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997–2008. Diabetes Care 2011; 34: 353–357.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る